SG Americas Securities LLC acquired a new stake in Arcus Biosciences Inc (NYSE:RCUS) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 8,782 shares of the company’s stock, valued at approximately $110,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of RCUS. Bank of Montreal Can increased its position in Arcus Biosciences by 2,591.0% in the first quarter. Bank of Montreal Can now owns 12,002 shares of the company’s stock worth $150,000 after buying an additional 11,556 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Arcus Biosciences by 1,931.5% in the first quarter. BNP Paribas Arbitrage SA now owns 6,521 shares of the company’s stock valued at $81,000 after purchasing an additional 6,200 shares in the last quarter. Bailard Inc. grew its position in shares of Arcus Biosciences by 53.2% in the first quarter. Bailard Inc. now owns 38,300 shares of the company’s stock valued at $478,000 after purchasing an additional 13,300 shares in the last quarter. Deutsche Bank AG grew its position in shares of Arcus Biosciences by 120.2% in the fourth quarter. Deutsche Bank AG now owns 40,986 shares of the company’s stock valued at $439,000 after purchasing an additional 22,370 shares in the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of Arcus Biosciences in the fourth quarter valued at $352,000. 46.58% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently issued reports on the company. Citigroup restated a “buy” rating and set a $25.00 price target on shares of Arcus Biosciences in a report on Friday, May 24th. Zacks Investment Research lowered Arcus Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Svb Leerink restated an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. Finally, BTIG Research initiated coverage on Arcus Biosciences in a report on Monday, March 18th. They set a “buy” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $17.50.
Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07). The business had revenue of $1.75 million during the quarter, compared to the consensus estimate of $1.25 million. Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.72%. As a group, analysts predict that Arcus Biosciences Inc will post -1.64 EPS for the current year.
In other news, President Juan C. Jaen purchased 10,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were purchased at an average cost of $8.25 per share, with a total value of $82,500.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Terry J. Rosen purchased 41,540 shares of the stock in a transaction dated Tuesday, June 4th. The shares were purchased at an average cost of $7.91 per share, for a total transaction of $328,581.40. The disclosure for this purchase can be found here. Insiders purchased a total of 105,343 shares of company stock worth $842,228 over the last ninety days. 19.23% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://weekherald.com/2019/06/12/sg-americas-securities-llc-takes-position-in-arcus-biosciences-inc-nysercus.html.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Featured Story: What are defining characteristics of a correction?
Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences Inc (NYSE:RCUS).
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.